DCN and Menkes disease: We also demonstrated, as a proof-of-principle experiment, that we could target a potential therapeutic molecule, DCN, to these lesions by CAR peptide and the targeted therapy is significantly better in suppressing the fibrosis formation than the non-targeted DCN therapy in the treatment of MD.